Sinovac Biotech Stock Book Value Per Share
Sinovac Biotech fundamentals help investors to digest information that contributes to Sinovac Biotech's financial success or failures. It also enables traders to predict the movement of Sinovac Stock. The fundamental analysis module provides a way to measure Sinovac Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinovac Biotech stock.
Sinovac |
Sinovac Biotech Company Book Value Per Share Analysis
Sinovac Biotech's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Sinovac Biotech Book Value Per Share | 2.83 X |
Most of Sinovac Biotech's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinovac Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Sinovac Biotech is about 2.83 times. This is 266.47% lower than that of the Healthcare sector and 101.14% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 99.85% higher than that of the company.
Sinovac Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinovac Biotech's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinovac Biotech could also be used in its relative valuation, which is a method of valuing Sinovac Biotech by comparing valuation metrics of similar companies.Sinovac Biotech is currently under evaluation in book value per share category among related companies.
Sinovac Fundamentals
| Return On Equity | 11.03 | ||||
| Return On Asset | 4.53 | ||||
| Profit Margin | 10.02 % | ||||
| Operating Margin | 15.86 % | ||||
| Current Valuation | 614.58 M | ||||
| Shares Outstanding | 98.9 M | ||||
| Shares Owned By Insiders | 15.89 % | ||||
| Shares Owned By Institutions | 23.11 % | ||||
| Number Of Shares Shorted | 199.77 K | ||||
| Price To Earning | 48.65 X | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 2.16 X | ||||
| Revenue | 213.17 M | ||||
| Gross Profit | 213.58 M | ||||
| EBITDA | 38.49 M | ||||
| Net Income | 15.35 M | ||||
| Cash And Equivalents | 176.72 M | ||||
| Cash Per Share | 1.79 X | ||||
| Total Debt | 93.13 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 2.98 X | ||||
| Book Value Per Share | 2.83 X | ||||
| Cash Flow From Operations | 22.17 M | ||||
| Short Ratio | 47.51 X | ||||
| Earnings Per Share | 0.13 X | ||||
| Number Of Employees | 910 | ||||
| Beta | 0.08 | ||||
| Market Capitalization | 460.25 M | ||||
| Total Asset | 202.98 M | ||||
| Retained Earnings | (8.28 M) | ||||
| Working Capital | 70.52 M | ||||
| Current Asset | 128.52 M | ||||
| Current Liabilities | 58 M | ||||
| Z Score | 3.4 |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Sinovac Stock
If you are still planning to invest in Sinovac Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinovac Biotech's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |